Dyadic International, Inc.

NasdaqCM:DYAI Stock Report

Market Cap: US$49.4m

Dyadic International Valuation

Is DYAI undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of DYAI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate DYAI's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate DYAI's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for DYAI?

Key metric: As DYAI is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for DYAI. This is calculated by dividing DYAI's market cap by their current revenue.
What is DYAI's PS Ratio?
PS Ratio17x
SalesUS$3.36m
Market CapUS$49.41m

Price to Sales Ratio vs Peers

How does DYAI's PS Ratio compare to its peers?

The above table shows the PS ratio for DYAI vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1.5x
CRIS Curis
3.3x41.1%US$34.7m
BNR Burning Rock Biotech
0.8xn/aUS$55.2m
ICCC ImmuCell
1.2xn/aUS$28.7m
FBIO Fortress Biotech
0.5x55.9%US$43.3m
DYAI Dyadic International
17x28.2%US$49.4m

Price-To-Sales vs Peers: DYAI is expensive based on its Price-To-Sales Ratio (17x) compared to the peer average (1.5x).

Price to Sales Ratio vs Industry

How does DYAI's PS Ratio compare vs other companies in the US Biotechs Industry?

129 CompaniesPrice / SalesEstimated GrowthMarket Cap
GILD Gilead Sciences
4x2.4%US$111.86b
BIIB Biogen
2.4x1.3%US$23.03b
MRNA Moderna
3.1x6.8%US$14.72b
INCY Incyte
3.4x8.9%US$13.56b
DYAI 17.0xIndustry Avg. 9.6xNo. of Companies129PS01632486480+
129 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: DYAI is expensive based on its Price-To-Sales Ratio (17x) compared to the US Biotechs industry average (9.6x).

Price to Sales Ratio vs Fair Ratio

What is DYAI's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

DYAI PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio17x
Fair PS Ratio3.4x

Price-To-Sales vs Fair Ratio: DYAI is expensive based on its Price-To-Sales Ratio (17x) compared to the estimated Fair Price-To-Sales Ratio (3.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst DYAI forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$1.93
US$7.50
+288.6%
20.0%US$9.00US$6.00n/a2
Nov ’25US$1.06
US$7.50
+607.5%
20.0%US$9.00US$6.00n/a2
Oct ’25US$1.03
US$7.50
+628.2%
20.0%US$9.00US$6.00n/a2
Sep ’25US$1.34
US$7.50
+459.7%
20.0%US$9.00US$6.00n/a2
Aug ’25US$1.35
US$7.50
+455.6%
20.0%US$9.00US$6.00n/a2
May ’25US$1.47
US$7.50
+410.2%
20.0%US$9.00US$6.00n/a2
Apr ’25US$1.67
US$7.50
+349.1%
20.0%US$9.00US$6.00n/a2
Mar ’25US$1.40
US$7.50
+435.7%
20.0%US$9.00US$6.00n/a2
Feb ’25US$1.38
US$7.50
+443.5%
20.0%US$9.00US$6.00n/a2
Jan ’25US$1.61
US$7.50
+365.8%
20.0%US$9.00US$6.00n/a2
Dec ’24US$1.77
US$7.50
+323.7%
20.0%US$9.00US$6.00n/a2
Nov ’24US$1.59
US$7.50
+371.7%
20.0%US$9.00US$6.00US$1.062
Oct ’24US$1.92
US$7.50
+290.6%
20.0%US$9.00US$6.00US$1.032
Sep ’24US$1.92
US$7.50
+290.6%
20.0%US$9.00US$6.00US$1.342
Aug ’24US$1.78
US$7.50
+321.3%
20.0%US$9.00US$6.00US$1.352
Jul ’24US$1.93
US$7.50
+288.6%
20.0%US$9.00US$6.00US$1.532
Jun ’24US$2.38
US$7.50
+215.1%
20.0%US$9.00US$6.00US$2.182
May ’24US$1.92
US$7.50
+290.6%
20.0%US$9.00US$6.00US$1.472
Apr ’24US$1.78
US$7.50
+321.3%
20.0%US$9.00US$6.00US$1.672
Mar ’24US$1.50
US$7.50
+400.0%
20.0%US$9.00US$6.00US$1.402
Feb ’24US$1.82
US$7.50
+312.1%
20.0%US$9.00US$6.00US$1.382
Jan ’24US$1.23
US$7.50
+509.8%
20.0%US$9.00US$6.00US$1.612
Dec ’23US$1.50
US$7.50
+400.0%
20.0%US$9.00US$6.00US$1.772
Nov ’23US$2.30
US$7.50
+226.1%
20.0%US$9.00US$6.00US$1.592

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

Collegium Pharmaceutical

US$967.5m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$30.41

7D

0.5%

1Y

17.1%

IQVIA Holdings

US$35.3b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$197.60

7D

-2.6%

1Y

-5.7%

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$55.86

7D

-5.2%

1Y

8.0%